About
Ambros Therapeutics is a clinical-stage biotechnology company developing neridronate, a third-generation bisphosphonate drug candidate, for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare and debilitating pain condition with no FDA-approved therapies.
Explore Ambros Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.